Budesonide
Catalog No.S1286
Molecular Weight(MW): 430.53
Budesonide is a glucocorticoid steroid for the treatment of asthma, non-infectious rhinitis.
Purity & Quality Control
Choose Selective Glucocorticoid Receptor Inhibitors
Biological Activity
| Description | Budesonide is a glucocorticoid steroid for the treatment of asthma, non-infectious rhinitis. | |
|---|---|---|
| Targets |
|
|
| In vitro |
Budesonide effectively inhibits production of eotaxin and RANTES protein although Budesonide inhibits the expression of chemokine mRNA to a variable extent in the human bronchial epithelial cell line BEAS-2B and in primary human bronchial epithelial cells. Budesonide inhibits both RANTES- and eotaxin promoter-driven reporter gene activity in the human bronchial epithelial cell line BEAS-2B and in primary human bronchial epithelial cells. Budesonide also selectively accelerates the decay of eotaxin and MCP-4 mRNA in the human bronchial epithelial cell line BEAS-2B and in primary human bronchial epithelial cells. [1] Budesonide time- and protein synthesis-dependently reduces VEGF secretion and VEGF mRNA expression in both cell types and these effects are inhibited by mifepristone (RU 486), a glucocorticoid receptor antagonist, suggesting that Budesonide reduces VEGF secretion and expression through its glucocorticoid receptor-mediated action. [2] Budesonide causes a dose-dependent, almost total, inhibition of swine dust-induced IL-6 and IL-8 release from epithelial cells and LPS-induced IL-6 and TNF-alpha from alveolar macrophages. [3] |
|
| In vivo | Budesonide totally prevents the increased production of TNF-alpha, interleukin (IL)-1beta, IL-6, and monocyte chemoattractive protein (MCP)-1 after LPS challenge at both low (2.5 mg/mL/kg) and high (50 mg/mL/kg) concentrations in rats. [4] Budesonide exerts its effects of chemoprevention through growth arrest via Mad2/3 and through apoptosis via Bim/Blk and, by inference, caspase-8/9 in A/J mice. [5] |
Protocol
Solubility (25°C)
| In vitro | DMSO | 86 mg/mL (199.75 mM) |
|---|---|---|
| Ethanol | 19 mg/mL (44.13 mM) | |
| Water | Insoluble |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 430.53 |
|---|---|
| Formula | C25H34O6 |
| CAS No. | 51333-22-3 |
| Storage | powder |
| Synonyms | N/A |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01950507 | Recruiting | Stem Cell Transplantation|Graft vs Host Disease | National Institutes of Health Clinical Center (CC)|National Heart, Lung, and Blood Institute (NHLBI) | August 31, 2013 | Phase 1 |
| NCT02853578 | Not yet recruiting | Asthma | Ache Laboratorios Farmaceuticos S.A. | March 2018 | Phase 3 |
| NCT02972866 | Not yet recruiting | Rhinitis, Allergic, Perennial | Eurofarma Laboratorios S.A. | October 2017 | Phase 3 |
| NCT01895075 | Not yet recruiting | Bronchopulmonary Dysplasia | Dr. Michael Dunn|Sunnybrook Health Sciences Centre | July 2017 | Phase 2 |
| NCT02941510 | Not yet recruiting | Altitude Sickness | University of Colorado, Denver | April 2017 | Phase 3 |
| NCT02991859 | Not yet recruiting | Asthma | GlaxoSmithKline | February 2017 | Phase 2 |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
